Eliana Rulli

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 557 citations · Full text

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 402 citations · Full text

Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

Annamaria Ruzzo, Francesco Graziano, Fotios Loupakis et al. · Journal of Clinical Oncology · 2007 · 264 citations · Full text

High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Daniele Santini, Fotios Loupakis, Bruno Vincenzi et al. · The Oncologist · 2008 · 228 citations